Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip‘s global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 13 June 2025, including: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories Mentioned In This Episode:
- Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart
- With ACIP Upheaval, Merck & Co. Among Those Left In A Lurch
- Merck & Co.’s RSV Antibody Approved In US In Time To Compete With Blockbuster Beyfortus
- Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms
- Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?
